Company Overview and News

1
What Analysts Are Saying About Oracle After Earnings

16m 247wallst
Oracle Corp. (NYSE: ORCL) released its fiscal first-quarter financial results after markets closed on Monday. While the report was not that great, it wasn’t half bad either. Analysts seemed to take a cue from this and their responses to the report were not uniform, with some taking a positive perspective and others still on the fence.
OCLCF ORCL

2
Microsoft Powers D365 With HoloLens & AI, Ups Ante in CRM

1h zacks
Microsoft (MSFT - Free Report) recently fortified its presence in the “mixed reality” (MR) space by introducing Dynamics 365 Remote Assist and Dynamics 365 Layout. This move is in sync with its bid to strengthen Dynamics 365 (“D365”) offering with HoloLens MR glasses. The new solutions are set to release on Oct 1, this year. Notably, the term “mixed reality” coined by the tech giant itself, implies a merger of Augmented Reality (AR) and Virtual Reality (VR) technologies.
MSFT ORCL CRM

6
It’s Time to Drop Oracle Stock and Never Pick It Up Again

10h investorplace
Regular readers know I am no fan of Oracle (NYSE:ORCL). Oracle stock has won some battles on behalf of proprietary software, but it is slowly losing the war. Even its Oracle Cloud, for which it had high hopes, lacks the scale and flexibility to compete.
IBM GOOGL MSFT GOOG CRM ORCL

8
Why Salesforce (CRM) Stock Is A Strong Buy Right Now

14h zacks
Shares of Salesforce (CRM - Free Report) are up over 7% in the last month as the customer relationship management firm continues its impressive run. So, let's take some time to see why Salesforce stock appears to be a strong buy even as it sits near its new high.
MDPEB MSFT MDP VMW ORCL

4
The Tesla of China & the Facebook-Macy's Connection | Free Lunch

20h zacks
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney recaps earnings results from Oracle and FedEx, discusses Trump’s new tariff announcement, and explains why Facebook and Macy’s have teamed up. Later, the host is joined by Dave Bartosiak to chat about Nio, the so-called Tesla of China.
ELY FB CY TXN FDX M ORCL RHT

6
Play Oracle's Q1 Earnings Beat With These 3 Tech Funds

22h zacks
Oracle Corporation (ORCL - Free Report) posted favorable earnings results in its fiscal first quarter. Although the software company posted a marginal revenue miss, on the earnings side, it's been two years since Oracle missed estimates.
CTCAX TXN MDPEB OCLCF MDP ORCL

6
Tech ETFs in Focus on Oracle's Mixed Bag Q1 Results

22h zacks
After the closing bell yesterday, software giant Oracle (ORCL - Free Report) reported fiscal first-quarter 2019 results. While the company beat the Zacks Consensus Estimate for earnings, it lagged on revenues and disappointed investors with a bleak outlook. Oracle Q1 Earnings in Focus Earnings per share came in at 71 cents, three cents ahead of the Zacks Consensus Estimate and up 18% year over year.
TDIV IGV TXN MDPEB MDP ORCL

1
Oracle: Getting Tired Of Waiting

23h seekingalpha
This is the fourth consecutive quarter that Oracle has disappointed on earnings. EPS beat this quarter, but flat revenue growth was underwhelming.
ORCL

6
Oracle (ORCL) Q1 Earnings Beat Estimates, Revenues Up Y/Y

23h zacks
Oracle Corporation (ORCL - Free Report) reported mixed first-quarter fiscal 2019 results. Non-GAAP earnings of 71 cents per share surpassed the Zacks Consensus Estimate of 68 cents. However, revenues of $9.2 billion marginally lagged the Zacks Consensus Estimate of $9.28 billion.
CY TXN MDPEB OCLCF MDP ORCL AZPN CRM

1
Albion Technology & General VCT PLC: Half-yearly Financial Report

2018-09-18 globenewswire
As required by the UK Listing Authority's Disclosure Guidance and Transparency Rule 4.2, Albion Technology & General VCT PLC today makes public its information relating to the Half-yearly Financial Report (which is unaudited) for the six months to 30 June 2018. This announcement was approved by the Board of Directors on 18 September 2018.
OCLCF LNSTY ORCL

47
Top Analyst Upgrades and Downgrades: AMD, Apache, Gold Fields, Marvell, Micron, Oracle, Starbucks, Transocean, United Rentals, Walmart and More

2018-09-18 247wallst - 4
Stocks were indicated to open higher on Tuesday. U.S. equity indexes remain very close to their all-time highs, while most international markets are not close to their highs. One issue that has to be considered is that investors have seen less upside from buying on market pullbacks than in prior years. Investors also need to consider how they want to have their investments positioned for the rest of 2018.
APA GFI.WI AMD WMT ISCA CL BKU MS RIG GFIOF ORCL MRVL FDX AKCA MU URI TRI SBUX GFI ESRX

21
AeroVironment, Meredith, Oracle and FedEx highlighted as Zacks Bull and Bear of the Day

2018-09-18 zacks
Chicago, IL – September 18, 2018 – Zacks Equity Research highlights AeroVironment Inc. (AVAV - Free Report) as the Bull of the Day, Meredith Corporation (MDP - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Oracle (ORCL - Free Report) and FedEx (FDX - Free Report) .
CVGI GFN GFNCP VTNR FDX AVAV MDP CVS JOUT GFNSL GTES MDPEB HEAR TIME GFDV ORCL

12
Market Snapshot: Stock futures edge up, but trade uncertainty remains in focus

2018-09-18 marketwatch
U.S. stock-index futures were slightly higher on Tuesday, though investors continued to monitor the latest development on the trade-policy front, which has recently shown signs of escalating.
GIS V AZO OCLCF MA ORCL

4
Is SurveyMonkey IPO Price Fair? Part 1: Analysis

2018-09-18 seekingalpha
Revenue is barely in the double-digit growth range, while that of user growth is even lower and slowing.
DBX MSFT CRM ORCL

1
Saudi's PIF invests more than US$1b in electric carmaker Lucid Motors

2018-09-18 malaymail
DUBAI, Sept 18 — Saudi Arabia's Public Investment Fund (PIF) has agreed to invest more than US$1 billion (RM4.14 billion) in Lucid Motors, adding to the emerging competition facing US electric vehicle maker Tesla Inc.
OCLCF 9984 SFTBF LCDXW SFTBY ORCL LCDX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ORCL / Oracle Corp. on message board site Silicon Investor.

Oracle Corporation (ORCL) Oracle Corporation (ORCL) Oracle Corporation (ORCL) Orcl split? Orcl split? Orcl split?
ORCL: Oracle Corporation ORCL: Oracle Corporation ORCL: Oracle Corporation SLNN, Development partner with ORCL/JAVA SLNN, Development partner with ORCL/JAVA SLNN, Development partner with ORCL/JAVA
Analyst Bashing (intc orcl mu amat csco) Analyst Bashing (intc orcl mu amat csco) Analyst Bashing (intc orcl mu amat csco) Oracle + Apple =? Oracle + Apple =? Oracle + Apple =?
Oracle - look out below!!!! Oracle - look out below!!!! Oracle - look out below!!!!
CUSIP: 68389X105